Additionally, a dual-targeting platform for CD44 has already been tested in hepatic tumors (e.g., HA- glycyrrhetinic acid -conjugated polymer to target liver) (232, 233) and breast cancer (e.g., HA-folic acid micelles for cells overexpressing the folic acid receptor) (234). This evidence concerns the gene CD44 and breast carcinoma.